1) Apricus Biosciences and Neopharm Group Sign Licensing Agreement for Vitaros (alprostadil) in Israel for up to $4.35 Million, Plus Royalties (Yahoo finance);
2) The Medicines Company and WilmerHale Law Firm Reach Settlement Agreement (Yahoo finance); Under the settlement agreement, The Medicines Company will receive approximately $18 million up front from WilmerHale’s professional liability insurers to cover certain past expenses. An additional $214 million will be available for damages in the event a generic bivalirudin is sold in the United States before June 15, 2015 as a result of the extension of the ‘404 patent being held invalid on the basis that the application for the extension was not timely filed.
3) Malaysia IPO: Patents (Amendment) Regulations 2011 will be effective from the date of 15th Feb 2011 (MYIPO)
4) Antwerp court stops infringement of valsartan/HCTZ SPC based on patent claiming valsartan alone (thespcblog)
5) BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program (Yahoo finance)
6) Eisai Concludes License Agreement for New Aricept Transdermal Formulation in japan (pharmalive); An adhesive skin patch containing donepezil hydrochloride seems to be protected by WO2007129427.
7) GSK Pharma to launch vaccine, cancer drugs in 2011 (Livemint); “The two oncology drugs, Revolade and Votrient, would be launched by end of first quarter or early second quarter“; The two cancer drugs seem to be protected in India. Revolade (eltrombopag) seems to be protected by 213176 (IN/PCT/2002/1666/MUM) and Votrient (Pazopanib) seems to be protected by210284 (818/KOLNP/2003).
8) Medivir AB Signs Dengue Deal with Johnson & Johnson (Press release)
· Collaboration with Janssen Pharmaceutica N.V. focused on dengue virus
· Both parties to contribute 50:50 resources to the research program
· Strengthens Medivir’s presence in infectious diseases and utilises strong know-how in the discovery of protease inhibitor drugs
10) Venus launches $2 mn super speciality cancer segment (BS)
11) Q-Med settles with Genzyme in US patent dispute (reuters); Genzyme Corporation filed a complaint in the District court of Massachusetts against Medicis alleging that Medicis is infringing on a patent held by Genzyme by marketing Restylane®, Perlane®, Restylane®-L and Perlane®-L in the United States . Now Q-Med said it would make a lump sum payment to Genzyme and Medicis had been released from any liability relating to the lawsuit. (View on RFCexpress); Patent involved: 5,399,351 (assigned to
12) Mylan Launches First Generic Version of Vfend® Tablets (Yahoo finance)
13) Actavis launches Anastrozole on day one in seven major European markets (Press release)